261 related articles for article (PubMed ID: 23009753)
1. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
[TBL] [Abstract][Full Text] [Related]
2. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
4. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
6. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Zhang D; McGregor M; Decker MW; Quik M
J Pharmacol Exp Ther; 2014 Oct; 351(1):25-32. PubMed ID: 25034405
[TBL] [Abstract][Full Text] [Related]
7. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Bordia T; McGregor M; McIntosh JM; Decker MW; Quik M
Mov Disord; 2014 Apr; 29(4):508-17. PubMed ID: 24515328
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
9. Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Quik M; Mallela A; Ly J; Zhang D
Mov Disord; 2013 Sep; 28(10):1398-406. PubMed ID: 23836409
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Bordia T; Campos C; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2010 Jun; 333(3):929-38. PubMed ID: 20200117
[TBL] [Abstract][Full Text] [Related]
11. Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
Bordia T; Perez XA; Heiss J; Zhang D; Quik M
Neurobiol Dis; 2016 Jul; 91():47-58. PubMed ID: 26921469
[TBL] [Abstract][Full Text] [Related]
12. Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum.
Leino S; Koski SK; Rannanpää S; Salminen O
Neurosci Lett; 2018 Apr; 672():40-45. PubMed ID: 29474871
[TBL] [Abstract][Full Text] [Related]
13. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
[TBL] [Abstract][Full Text] [Related]
14. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
15. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
17. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Cox H; Togasaki DM; Chen L; Langston JW; Di Monte DA; Quik M
Exp Neurol; 2007 May; 205(1):101-7. PubMed ID: 17335811
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
19. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D
Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553
[TBL] [Abstract][Full Text] [Related]
20. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]